Propulsid Gave Too Little Benefit, Put Far Too Many At Risk

Even before Johnson & Johnson halted sales of the nocturnal heartburn medication Propulsid in 2000 (following consultations with the Food and Drug Administration) the drug's label contained a long warning list of contraindicated medications and underlying health conditions that dramatically increased risks to patients.

The manufacturer claimed that harmful effects of Propulsid were mainly due to combined use with contraindicated drugs, however, even now it is unclear whether any of the contraindicated drugs had anything to do with the harmful effects of Propulsid.

HermanGerel has been in the forefront of nationwide litigation involving Propulsid. And we can help you -- or someone you know who has taken Propulsid -- to join the litigation. Click here to have one of our attorneys evaluate your potential claim.

Originally, cisapride (the active ingredient in Propulsid) was approved by FDA in tablet form in 1993 and in suspension form in 1995. Yet unlike drugs that reduce stomach acid, cisapride was said to work by a prokinetic mechanism that moves harmful acids through the digestive tract, which purportedly reduced painful reflux into the esophagus.

But it is unclear whether this mechanism of action was ever proven to occur, or that Propulsid ever benefited those who took it. In addition, no accurate warnings regarding cardiac risks of cisapride were ever issued.

To view updates on Propulsid, look in news items.

Home | About Us | Types of Cases | In the News | Attorney Listing | Do I Have a Case? | Site Map | Search Site | Contact Us | Web Resources